In conclusion, our study suggested a novel involvement of circPIP5K1A in a cross talk between miR5523p/JAK1/STAT3 pathways in β-cells as a new therapeutic target for T2DM. The gene discussed is STAT3; the disease is type 2 diabetes mellitus.